Now that the FDA has forced GlaxoSmithKline (GSK) to put a "black label" on its diabetes drug Avandia, the competition is going for a coup de grace.
Takeda Pharmaceutical Co Ltd said on Thursday it was planning a major U.S. advertising campaign for diabetes drug Actos — one day after a new safety warning was issued on rival product Avandia, according to Reuters. The news service adds "the ads will run in 82 local newspapers and in several news weeklies, starting on Friday, under the headline "Actos has been shown to lower blood sugar without increasing your risk of having a heart attack or stroke.".
Never let it be said that the drug company executives are nice people.
Douglas A. McIntyre
“The Next NVIDIA” Could Change Your Life
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
